Stephanie Venn-Watson, the lead author and co-founder of Seraphina Therapeutics
Endocrinology 153 , 574582, doi:10.1210/En.2011-0259 (2012)
Short bowel patients treated for two years with glucagon-like peptide 2: Effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function
A comprehensive clinic will look at all this and more, addressing stress management, eating, exercise, sleep, hydration and mental health too
It added that 170,000 people are taking the drug at the moment, many of whom appear to be new to GLP-1 agonist therapy for weight loss as they are using the starter dose, which sells for $149 per month